查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1483119

高度活躍的 API 市場評估：依產品、依合成、依藥物類型、依製造商、依應用、依地區、機會、預測，2017-2031 年

High Potency APIs Market Assessment, By Product, By Synthesis, By Type of Drug, By Manufacturer, By Application, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 232 Pages | 商品交期: 3-5個工作天內

價格

全球高度活躍的 API 市場規模預計將從 2023 年的 252.3 億美元成長到 2031 年的 478.1 億美元，2024-2031 年預測期間複合年增長率為 8.32%。癌症發病率上升以及致力於使製造過程更有效率、更安全的技術突破推動了市場擴張。

由於癌症盛行率上升，對癌症治療藥物的需求不斷增加，推動了對全球高度活躍的 API 市場的需求。癌症是導致死亡的主要原因之一，2022 年將通報新增 2,000 萬癌症病例。到 2040 年，這一數字預計將增至 2,990 萬。癌症患者數量的增加預計將推動對高效活性藥物成分的需求，而高效活性藥物成分是標靶治療的關鍵組成部分。

該報告調查了全球高度活躍的 API 市場，並提供了市場概況，以及依產品類型、合成、藥物類型、製造商、應用、地區和進入市場的公司概況劃分的趨勢。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章執行摘要

第四章 2017-2031 年全球高度活躍的 API 市場展望

  • 市場規模及預測
  • 依產品
  • 依成分分類
  • 依藥物類型
  • 依製造商
  • 依用途
  • 依地區
  • 依公司劃分的市佔率 (%)，2023 年

第 5 章 2017-2031 年全球高度活躍的 API 市場展望（依地區）

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章 市場測繪，2023 年

第七章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第八章市場動態

第九章 監理架構與創新

第十章 主要與企業狀況

第11章價格分析

第十二章案例研究

第十三章 主要進入者展望

  • Pfizer, Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Abbvie Inc.
  • F. Hoffmann-La Roche Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Bayer AG
  • Bristol-Myers Squibb Company

第十四章 戰略建議

第十五章 查詢及免責聲明

Product Code: MX11352

Global high potency APIs market is projected to witness a CAGR of 8.32% during the forecast period 2024-2031F, growing from USD 25.23 billion in 2023 to USD 47.81 billion in 2031F. The market expansion is supported by the increasing prevalence of cancer and breakthroughs in technologies that are focused on enhancing the efficiency of the manufacturing processes and improving safety.

The growing requirement for oncology drugs due to the increasing prevalence of cancer is boosting the global high-potency APIs market demand. Cancer is one of the leading causes of deaths and in 2022, 20 million new cases of cancer were reported. The number is expected to rise to 29.9 million by 2040. The rise in the number of cases of cancer is expected to propel the requirement for high potency active pharmaceutical ingredients as they are a critical component of targeted therapies.

Various science and technology companies are heavily investing in expanding their manufacturing facilities to meet the growing demand for cancer therapies. In June 2023, Merck opened a new CDMO facility to meet the increasing demand for critical cancer therapies. Such developments are boosting the demand for high potency active pharmaceutical ingredients (APIs) due to the growing preference for targeted therapeutics.

The expiration of various patents and increasing efforts to develop cost-efficient and generic drug substitutes are another major driver augmenting the market's growth. The demand for high-potency active pharmaceutical ingredients (HPAPIs) from the healthcare sector can be attributed to their effective functioning at low doses.

Rising Investments in Production Facilities Boost Global High Potency APIs Market Size

Various market players are actively investing in developing and expanding their high potency active pharmaceutical ingredients and active pharmaceutical ingredients (API) facilities. Piramal Pharma began production of HPAPIs and APIs in 2023 in their Michigan facility after expanding the site's production capacity. The company invested USD 38 million on the expansion of their Riverview site. The size of the new site is approximately 25,000 square feet and has production and warehousing facilities. The company added 10,000 L retractor capacity in the facility for ensuring that the production of HPAPIs is completed with low occupation exposure levels. The site has product isolation capabilities including distillation, extraction, centrifugation, and filtration. Such investments are expected to provide lucrative growth opportunities for the market in the coming years as they will bolster the production of high potency active pharmaceutical ingredients. These investments are expected to allow the market players to expand their customer base and aid them in catering to the evolving and growing demands of their customers.

Increasing Mergers and Acquisitions Provide Lucrative Growth Opportunities to the Market

Increased collaborations, acquisitions, and mergers are expected to boost the development of various drugs, propelling the requirement for high-potency active pharmaceutical ingredients. For instance, in December 2023, Pfizer announced the completion of the acquisition of Seagan. Pfizer completed the acquisition of the biotechnology company for approximately USD 43 billion. Seagan's leading antibody drug conjugate (ADC) technology combined with the strength and scale of Pfizer's expertise and capabilities is expected to shift the cancer treatment paradigm. The antibody drug conjugate technology offered by Seagan is a transformative modality emerging as an innovative tool across a wide range of cancers. The technology is designed to kill cancer cells while limiting off-target toxicities. After the completion of the acquisition, Pfizer's oncology portfolio includes twenty-five approved biosimilars and medicines across more than forty indications. Such mergers and acquisitions are expected to support global high potency APIs market growth.

North America Holds a Significant Share of the Market

The growth of the market in the region can be attributed to the rapid expansion of the healthcare sector in the region, increasing awareness about the various benefits of high potency APIs, and strong presence of various pharmaceutical and biotechnology companies. The market expansion is further supported by increasing prevalence of chronic diseases in the United States of America and Canada. According to the estimates of the Canadian Cancer Society, two out of five Canadians are expected to receive a cancer diagnosis in their lifetime and one in four Canadians are expected to die due to the chronic disease. The growing prevalence of such conditions is propelling the demand for effective drugs for management of the disease, which in turn, is bolstering the requirement for high potency active pharmaceutical ingredients. High potency APIs are witnessing an increase in demand due to their ability to deliver targeted treatments at low doses, reducing the number of side effects.

Generic High Potency Active Pharmaceutical Ingredients Account for Significant Market Share

The expiration of various patents in the coming years supports the segment's expansion in the global high potency APIs market. For instance, the patent of Keytruda by Merck and Co. will expire in 2028. The performance of the drug is supported by its multiple indications that include kidney cancer, bladder cancer, metastatic non-small cell lung cancer, and post-surgery melanoma, among others. The quality analysis of generic high potency active pharmaceutical ingredients involves a comparative study between in vivo and in vitro evaluations. The in vitro evaluation methods involve key indicators of internal quality, including crystal type and raw material. Various APIs have specific number of molecules, ions and atoms, and crystal structure, allowing them to provide specific polycrystalline diffraction patterns. The in vivo evaluation methods focus on clinical efficacy tests and bioequivalence tests to ensure the quality of generic high potency active pharmaceutical ingredients.

Oncology Accounts for Significant Global High Potency APIs Market Share

A new era of targeted cancer therapies has been ignited with the help of antibody-drug conjugates (ADCs). ADC technology utilizes monoclonal antibodies among other biologics for delivering high potency active pharmaceutical ingredients to the targeted cells. The high potency active pharmaceutical ingredients exhibit advanced selective therapeutic activity, improving the safety profile by sparing non-target cells from the toxic effects. The growing burden of cancer across the globe is bolstering the requirement for high potency active pharmaceutical ingredients for oncology applications. According to the estimates of the American Cancer Society, 1,958,310 new cases of cancer and 609,820 deaths related to cancer were projected to occur in the United States in 2023. The increase is expected to bolster the demand for oncology drugs, propelling the market's growth as these drugs require high potency active pharmaceutical ingredients due to their ability to elicit a biological response at low concentrations.

Future Market Scenario (2024 - 2031F)

According to global high potency APIs market analysis, technological advancements and the evolving requirements of the pharmaceutical sector, due to increasing shift towards potent and targeted molecules for drug development and discovery will provide lucrative growth opportunities to the market. The high potency APIs require strong containment strategies and stringent handling requirements to ensure the safety of the workers. To meet the challenges provided by these APIs, teams across the pipeline need to leverage specific skills, technologies, and systems to meet the standard of containment procedures for avoiding potential cross-contamination and guaranteeing the safety of the operators. Despite various risks associated with HPAPIs, they have emerged as a novel class of pharmaceuticals because of their potential to provide various therapeutic and patient benefits. The rising requirement for effective oncology treatments is expected to further boost the demand for high potency APIs. These molecules can be used in combination therapies, as immuno-oncology agents and as standalone therapies.

Key Players Landscape and Outlook

The major players in the high potency APIs market are Pfizer, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Abbvie Inc., and F. Hoffmann-La Roche Ltd. The market growth is supported by increasing investments by various companies towards the expansion of their facilities. In January 2024, Olon Group announced a new GMP High Potency Active Pharmaceutical Ingredient (HPAPI) suite, that is under construction in Ohio, United States. The new HPAPI suite is engineered to meet the stringent safety standards for GMP processes and research and development and will operate for materials that have an OEL of <1 µg/m3. The suite will provide a self-contained and secure environment for working with such materials while ensuring the safety of the staff and operators. The suit will allow the company to support a broad range of therapeutic indications and clients, aiding the development of innovative and novel therapies.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global High Potency APIs Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Product
    • 4.2.1.Innovative High Potency Active Pharmaceutical Ingredient
    • 4.2.2.Generic High Potency Active Pharmaceutical Ingredient
  • 4.3.By Synthesis
    • 4.3.1.Biotech High Potency Active Pharmaceutical Ingredients
    • 4.3.2.Synthetic High Potency Active Pharmaceutical Ingredients
  • 4.4.By Type of Drug
    • 4.4.1.Branded
    • 4.4.2.Generic
  • 4.5.By Manufacturer
    • 4.5.1.Outsourced
    • 4.5.2.In-house
  • 4.6.By Application
    • 4.6.1.Oncology
    • 4.6.2.Glaucoma
    • 4.6.3.Hormonal Disorders
    • 4.6.4.Others
  • 4.7.By Region
    • 4.7.1.North America
    • 4.7.2.South America
    • 4.7.3.Europe
    • 4.7.4.Asia-Pacific
    • 4.7.5.Middle East & Africa
  • 4.8.By Company Market Share (%), 2023

5.Global High Potency APIs Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Product
      • 5.1.2.1.Innovative High Potency Active Pharmaceutical Ingredient
      • 5.1.2.2.Generic High Potency Active Pharmaceutical Ingredient
    • 5.1.3.By Synthesis
      • 5.1.3.1.Biotech High Potency Active Pharmaceutical Ingredients
      • 5.1.3.2.Synthetic High Potency Active Pharmaceutical Ingredients
    • 5.1.4.By Type of Drug
      • 5.1.4.1.Branded
      • 5.1.4.2.Generic
    • 5.1.5.By Manufacturer
      • 5.1.5.1.Outsourced
      • 5.1.5.2.In-house
    • 5.1.6.By Application
      • 5.1.6.1.Oncology
      • 5.1.6.2.Glaucoma
      • 5.1.6.3.Hormonal Disorders
      • 5.1.6.4.Others
    • 5.1.7.United States*
      • 5.1.7.1.Market Size & Forecast
        • 5.1.7.1.1.By Value
        • 5.1.7.1.2.By Volume
      • 5.1.7.2.By Product
        • 5.1.7.2.1.Innovative High Potency Active Pharmaceutical Ingredient
        • 5.1.7.2.2.Generic High Potency Active Pharmaceutical Ingredient
      • 5.1.7.3.By Synthesis
        • 5.1.7.3.1.Biotech High Potency Active Pharmaceutical Ingredients
        • 5.1.7.3.2.Synthetic High Potency Active Pharmaceutical Ingredients
      • 5.1.7.4.By Type of Drug
        • 5.1.7.4.1.Branded
        • 5.1.7.4.2.Generic
      • 5.1.7.5.By Manufacturer
        • 5.1.7.5.1.Outsourced
        • 5.1.7.5.2.In-house
      • 5.1.7.6.By Application
        • 5.1.7.6.1.Oncology
        • 5.1.7.6.2.Glaucoma
        • 5.1.7.6.3.Hormonal Disorders
        • 5.1.7.6.4.Others
    • 5.1.8.Canada
    • 5.1.9.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Product
  • 6.2.By Synthesis
  • 6.3.By Type of Drug
  • 6.4.By Manufacturer
  • 6.5.By Application
  • 6.6.By Region

7.Macro Environment and Industry Structure

  • 7.1.Supply Demand Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Patent Landscape
  • 9.2.Regulatory Approvals
  • 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Pfizer, Inc.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Novartis AG
  • 13.3.Teva Pharmaceutical Industries Ltd.
  • 13.4.Abbvie Inc.
  • 13.5.F. Hoffmann-La Roche Ltd
  • 13.6.Sun Pharmaceutical Industries Ltd.
  • 13.7.Merck & Co., Inc.
  • 13.8.Sanofi S.A.
  • 13.9.Bayer AG
  • 13.10.Bristol-Myers Squibb Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 3.Global High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 4.Global High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 5.Global High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 6.Global High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 7.Global High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 8.Global High Potency APIs Market Share (%), By Region, 2017-2031F
  • Figure 9.North America High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 10.North America High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 11.North America High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 12.North America High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 13.North America High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 14.North America High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 15.North America High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 16.North America High Potency APIs Market Share (%), By Country, 2017-2031F
  • Figure 17.United States High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 18.United States High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 19.United States High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 20.United States High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 21.United States High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 22.United States High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 23.United States High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 24.Canada High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 25.Canada High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 26.Canada High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 27.Canada High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 28.Canada High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 29.Canada High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 30.Canada High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 31.Mexico High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 32.Mexico High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 33.Mexico High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 34.Mexico High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 35.Mexico High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 36.Mexico High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 37.Mexico High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 38.Europe High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 39.Europe High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 40.Europe High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 41.Europe High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 42.Europe High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 43.Europe High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 44.Europe High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 45.Europe High Potency APIs Market Share (%), By Country, 2017-2031F
  • Figure 46.Germany High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.Germany High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 48.Germany High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 49.Germany High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 50.Germany High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 51.Germany High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 52.Germany High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 53.France High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 54.France High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 55.France High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 56.France High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 57.France High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 58.France High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 59.France High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 60.Italy High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 61.Italy High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 62.Italy High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 63.Italy High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 64.Italy High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 65.Italy High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 66.Italy High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 67.United Kingdom High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 68.United Kingdom High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 69.United Kingdom High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 70.United Kingdom High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 71.United Kingdom High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 72.United Kingdom High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 73.United Kingdom High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 74.Russia High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 75.Russia High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 76.Russia High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 77.Russia High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 78.Russia High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 79.Russia High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 80.Russia High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 81.Netherlands High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 82.Netherlands High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 83.Netherlands High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 84.Netherlands High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 85.Netherlands High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 86.Netherlands High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 87.Netherlands High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 88.Spain High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Spain High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 90.Spain High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 91.Spain High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 92.Spain High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 93.Spain High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 94.Spain High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 95.Turkey High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 96.Turkey High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 97.Turkey High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 98.Turkey High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 99.Turkey High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 100.Turkey High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 101.Turkey High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 102.Poland High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 103.Poland High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 104.Poland High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 105.Poland High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 106.Poland High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 107.Poland High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 108.Poland High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 109.South America High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 110.South America High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 111.South America High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 112.South America High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 113.South America High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 114.South America High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 115.South America High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 116.South America High Potency APIs Market Share (%), By Country, 2017-2031F
  • Figure 117.Brazil High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 118.Brazil High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 119.Brazil High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 120.Brazil High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 121.Brazil High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 122.Brazil High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 123.Brazil High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 124.Argentina High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 125.Argentina High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 126.Argentina High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 127.Argentina High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 128.Argentina High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 129.Argentina High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 130.Argentina High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 131.Asia-Pacific High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 132.Asia-Pacific High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 133.Asia-Pacific High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 134.Asia-Pacific High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 135.Asia-Pacific High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 136.Asia-Pacific High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 137.Asia- Pacific High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 138.Asia-Pacific High Potency APIs Market Share (%), By Country, 2017-2031F
  • Figure 139.India High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 140.India High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 141.India High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 142.India High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 143.India High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 144.India High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 145.India High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 146.China High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 147.China High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 148.China High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 149.China High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 150.China High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 151.China High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 152.China High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 153.Japan High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 154.Japan High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 155.Japan High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 156.Japan High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 157.Japan High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 158.Japan High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 159.Japan High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 160.Australia High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 161.Australia High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 162.Australia High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 163.Australia High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 164.Australia High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 165.Australia High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 166.Australia High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 167.Vietnam High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 168.Vietnam High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 169.Vietnam High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 170.Vietnam High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 171.Vietnam High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 172.Vietnam High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 173.Vietnam High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 174.South Korea High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 175.South Korea High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 176.South Korea High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 177.South Korea High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 178.South Korea High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 179.South Korea High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 180.South Korea High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 181.Indonesia High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.Indonesia High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 183.Indonesia High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 184.Indonesia High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 185.Indonesia High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 186.Indonesia High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 187.Indonesia High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 188.Philippines High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 189.Philippines High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 190.Philippines High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 191.Philippines High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 192.Philippines High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 193.Philippines High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 194.Philippines High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 195.Middle East & Africa High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 196.Middle East & Africa High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 197.Middle East & Africa High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 198.Middle East & Africa High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 199.Middle East & Africa High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 200.Middle East & Africa High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 201.Middle East & Africa High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 202.Middle East & Africa High Potency APIs Market Share (%), By Country, 2017-2031F
  • Figure 203.Saudi Arabia High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 204.Saudi Arabia High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 205.Saudi Arabia High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 206.Saudi Arabia High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 207.Saudi Arabia High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 208.Saudi Arabia High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 209.Saudi Arabia High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 210.UAE High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 211.UAE High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 212.UAE High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 213.UAE High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 214.UAE High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 215.UAE High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 216.UAE High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 217.South Africa High Potency APIs Market, By Value, In USD Billion, 2017-2031F
  • Figure 218.South Africa High Potency APIs Market, By Volume, In Kilotons, 2017-2031F
  • Figure 219.South Africa High Potency APIs Market Share (%), By Product, 2017-2031F
  • Figure 220.South Africa High Potency APIs Market Share (%), By Synthesis, 2017-2031F
  • Figure 221.South Africa High Potency APIs Market Share (%), By Type of Drug, 2017-2031F
  • Figure 222.South Africa High Potency APIs Market Share (%), By Manufacturer, 2017-2031F
  • Figure 223.South Africa High Potency APIs Market Share (%), By Application, 2017-2031F
  • Figure 224.By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225.By Synthesis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226.By Type of Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227.By Manufacturer Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228.By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023